In the last decade, there have been major advances in the understanding of the role of glial cells as key elements in the formation, maintenance and refinement of synapses. Recently, the discovery of natural compounds capable of modulating nervous system function has revealed new perspectives on the restoration of the injured brain. Among these compounds, flavonoids stand out as molecules easily obtainable in the diet that have remarkable effects on cognitive performance and behavior. Nevertheless, little is known about the cellular and molecular mechanisms underlying the actions of flavonoids in the nervous system. The present review presents recent advances in the effects of natural compounds, particularly flavonoids, in the nervous system. We shed light on astrocytes as targets of flavonoids and discuss how this interaction might contribute to the effects of flavonoids on neuronal survival, differentiation and function. Finally, we discuss how the effects of flavonoids on astrocytes might contribute to the development of alternative therapeutic approaches to the treatment of neural diseases.
Introduction
In the last two decades, there have been huge advances in research on glial cells, and those cells have emerged as key mediators of several processes in the healthy and injured brain. Additionally, astrocytes have been widely implicated in several neurodegenerative diseases and neurological disorders, suggesting that glial cells might be potential targets for therapeutic approaches to the treatment of those diseases, once we better understand the underlying mechanisms of neuroneastrocyte interactions.
In the present review, we will focus on the role of astrocytes as mediators of flavonoid action in the brain. First, we will present an overview of the effects of natural compounds, particularly flavonoids, on brain function, focusing on neuronal cells. Then, we will discuss the new concept of astrocytes as mediators of synapse formation and address the novel role of astrocytes as mediators of polyphenol action in the central nervous system (CNS). Finally, we will briefly discuss the emerging view of astrocytes as essential players in neurodegenerative diseases and how a better understanding of the actions of flavonoids might contribute to the of new therapeutic approaches to the treatment of brain pathologies.
Flavonoids and the CNS
Flavonoids are low molecular weight compounds with a diphenylpropane skeleton (C6eC3eC6), consisting of two aromatic rings, designated A and B, which are joined by three carbon atoms, forming a third ring (called C), oxygenated and heterocyclic (RiceEvans et al., 1996) . Over 4000 different varieties of flavonoids have been identified, and classified into six major groupsdflavanols, flavonols, flavanones, isoflavones, catechins and anthocyaninsdaccording to their different molecular structures (Manach et al., 2004; Nijveldt et al., 2001 ). These subclasses differ in the degree of oxidation of their three-carbon chain, the pattern of hydroxylation of the ring structure and the substitution at the 3 0 position (Croft, 1998) .
Flavonoids comprise the most common group of polyphenolic compounds in the human diet, as they are ubiquitously present in fruits, vegetables, cereals, teas and wines (Beecher, 2003) . Studies indicate that the intake of these compounds is inversely related to the mortality caused by heart disease (Knekt et al., 1996) and to cognitive decline during aging (Devore et al., 2012) .
After ingestion, most flavonoids are metabolized in the gastrointestinal tract and liver, are absorbed into the bloodstream and can reach the CNS by crossing the bloodebrain barrier (BBB) (Rodriguez-Mateos et al., 2014) . To date, there is little information about the bioavailability of flavonoids and their ability to reach the CNS. The detection of some polyphenols and their metabolites in different brain areas after the oral administration of polyphenolic extracts in murine models indicates that at least some flavonoids are able to cross the BBB (Abd El Mohsen et al., 2002; Ferruzzi et al., 2009) . Recently, it has been demonstrated that the consumption of a diet high in cocoa flavanol enhances dentate gyrus function and improves cognitive abilities in healthy 50e69-year-old subjects (Brickman et al., 2014) .
Although the mechanism of action of flavonoids is still a subject of discussion, several flavonoid-binding sites have been reported, including adenosine receptors, GABAA (g-aminobutyric acid type A receptor), d-opioid, nicotinic, estrogen, and testosterone receptors . Interestingly, the first flavonoid described as a receptor agonist was 7,8 dihydroxyflavone (7,8-DHF), a small flavone able to induce the dimerization and autophosphorylation of TrkB receptors on neurons and thus reduced neuronal death in vitro and in vivo . Since then, many other studies have shown the benefits of the administration of 7,8-DHF in animal models of neurodegenerative and neurological diseases because it promotes behavioral phenotypes similar to those induced by brain-derived neurotrophic factor (BDNF) (Devi and Ohno, 2012; Liu et al., 2010; Tian et al., 2015; Zeng et al., 2012; Zhao et al., 2015) .
Together, these data shed light on the potential role of flavonoids as therapeutic agents for neural diseases associated with cognitive deficits. However, flavonoids have not yet been successfully used as therapeutic agents due to insufficient knowledge regarding their metabolism and mechanism of action. These data indicate that understanding the cellular mechanisms of action of these natural compounds is important to fully explore their potential as neurological agents.
Effects of flavonoids on neuronal function
Synaptic transmission is the basis for all cognitive processes and allows the interaction of an organism with its environment. Moreover, synaptic dysfunction has a significant impact on neuronal physiology and consequently the functioning of the CNS. These changes occur during the physiological aging process and are, among other causes, related to the decline of cognitive functions (Morrison and Baxter, 2012; Shi et al., 2015) . Furthermore, in recent years, several studies have shown that synaptic deficits also occur in early stages of some neurodegenerative diseases, where they precede neuronal death (DeKosky et al., 1996; Rutten et al., 2005) . Therefore, the modulation of synaptic function and neuronal survival are important strategies in the prevention of agerelated cognitive decline and in the treatment of neural diseases. In this context, natural compounds appear to be promising therapeutic agents because they may affect neuronal survival and differentiation, neurogenesis in the adult and, as recently described, synaptic function and plasticity.
We have previously demonstrated the neuroprotective actions of some flavonoids in vitro. The glycosidic flavanone, hesperidin, is able to induce the differentiation of progenitor cells in neurons and protect them from death via the activation of the MAPK and PI3K pathways (Nones et al., 2011) . We have reported similar data in cortical progenitor cells treated with casticin, a flavone obtained from organic extracts of Brazilian Croton betulaster (de Sampaio e Spohr et al., 2010) . Moreover, flavonoids hesperidin and rutin have been shown to increase neural crest cell survival in vitro (Nones et al., 2012a) , suggesting that these flavonoids act not only on the cells in the CNS but that they might also control the survival of peripheral nervous system (PNS) cells.
In addition to the neuroprotective effects, several lines of evidence have shown that flavonoids may modulate neuronal function. The flavanol (À) epicatechin increased the expression and levels of the GluR2 subunit of the AMPA receptor and induced CREB phosphorylation in cortical neurons (Schroeter et al., 2007) . Another in vitro study has shown that the active components of Ginkgo biloba extract, quercetin and bilobalide, increased the number of dendrites in hippocampal neurons (Tchantchou et al., 2009 ). Additionally, a screening of 65 flavonoids has shown the capacity of different flavonoids, mainly (À)-catechin, luteolin and isorhamnetin, to increase the expression of synaptic proteins (Xu et al., 2013b) . The functional impact of these actions has been shown in different in vitro and in vivo models. The flavonoid fisetin facilitates long-term potentiation (LTP) in the pyramidal cells of CA1 hippocampal slices and improves memory in animals on a flavonoid-supplemented diet (Maher et al., 2006) . Recent studies have shown that 7,8-DHF was able to promote dendrite branching and synapse formation in cortical neurons as well as prevent the loss of synapses and memory deficits in a mouse model of Alzheimer's disease (Zhang et al., 2014) and cognitive and spine abnormalities in a murine model of fragile X syndrome (Tian et al., 2015) .
Together, these studies suggest that flavonoids impact neuronal function and modulate neurotransmission, synaptic plasticity and cognitive improvements. However, mechanisms of action of flavonoids, including their direct effects on synapses and their actions in different cell types that make up the nervous system, are not fully understood.
Astrocytes as mediators of flavonoid action

Astrocytes and synapses
Astrocytes represent a large population of cells in the mammalian brain. Although they were initially considered a homogenous population, it is now known that astrocytes are highly heterogeneous in their morphology and function (Nedergaard et al., 2003) .
Astrocytes form a syncytial structure, where they are coupled together by gap junctions. Thus, they fill spaces between neuronal axons and synaptic terminals and play crucial roles in metabolic control, including in the processes of ionic regulation, the modulation of CO 2 concentration, neurotransmitter uptake and the control of extracellular pH. Furthermore, these cells are the main source of growth and neurotrophic factors, which are essential for neurogenesis, cell migration, differentiation, synaptogenesis and synaptic plasticity (Diniz et al., 2014a; Dodla et al., 2010; Spohr et al., 2008; Stipursky and Gomes, 2007) .
Astrocytes control synapse formation via two different mechanisms, namely the secretion of soluble factors and the expression of contact molecules. Since the late 1990s, several synaptogenic molecules derived from astrocytes have been described, including thrombospondin (Christopherson et al., 2005; Crawford et al., 2012; Garcia et al., 2010; Hennekinne et al., 2013) , cholesterol (Mauch et al., 2001) , hevin (Kucukdereli et al., 2011; Risher et al., 2014) , secreted protein acidic and rich in cysteine (SPARC) (Albrecht et al., 2012; Jones et al., 2011; Kucukdereli et al., 2011) , glypicans 4 and 6 (Allen et al., 2012) , estrogen (Hu et al., 2007) , Dserine (Henneberger et al., 2010) , tumor necrosis factor alpha (TNFa) (Stellwagen and Malenka, 2006) , transforming growth factor beta 1 (TGF-b1) (Diniz et al., 2012 (Diniz et al., , 2014b Fuentes-Medel et al., 2012) and BDNF (Gomez-Casati et al., 2010) .
Recently, we described a novel function of human and murine astrocytes in balancing the excitatory and inhibitory inputs in the cerebral cortex through the activation of TGF-b1 pathway (Diniz et al., 2014a) : 1). By inducing the synthesis of D-serine, a coagonist of NMDA receptors, astrocytes induce the formation of excitatory synapses (Diniz et al., 2012) ; 2) by activating the Ca 2þ / calmodulin-dependent protein kinase (CAMKII), and by inducing the cluster of the trans-synaptic adhesion protein neuroligin 2 in inhibitory postsynaptic terminals, astrocytes promote inhibitory synapse formation (Diniz et al., 2014b) . Taken together with other studies, our data suggest that the TGF-b1 pathway is highly conserved in invertebrates and vertebrates, including humans, to control synapse formation and function.
Recently, an elegant study presented the first direct in vivo evidence for the role of human astrocytes in synaptic plasticity, learning and memory. The injection of human glial progenitor cells into the brain led to an improvement in synaptic plasticity and learning, possibly through the regulation of TNF-a synthesis (Modi et al., 2013) . These data suggest that although some synaptogenic pathways induced by astrocytes are conserved between species, it is likely that human astrocytes might have developed specific pathways that allowed them to improve learning and cognition. These data suggest that the manipulation of astrocyte function might represent a potential tool to control cognitive functions and, eventually, to rescue synaptic deficits.
The effects of flavonoids on astrocyte function: implications for synaptic plasticity and cognition
In vivo studies have demonstrated that chronic treatment with extracts enriched with polyphenols or purified flavonoids induces cognitive and behavioral improvements. These effects were associated with increased levels of neurotrophic factors in the brain (Rendeiro et al., 2012; Williams et al., 2008) . Supplementation with blueberry extract in young and aged rats increased BDNF levels in the hippocampus and improved spatial working memory in mice (Rendeiro et al., 2012; Williams et al., 2008) . In addition, chronic treatment with the flavanone hesperidin has been shown to increase BDNF levels in the hippocampus of treated animals, suggesting a putative mechanism for the antidepressant-like effect of flavonoids (Donato et al., 2014) .
Although current data corroborate the promising actions of flavonoids in the CNS, little is known about their cellular targets in vivo. Several works have discussed the beneficial effects of flavonoids on both human and animal brain function, although their impact in glial cells has been neglected (see Rendeiro et al., 2015;  for review). The observation that glial cells, especially astrocytes, are the main source of trophic factors in the CNS and are highly implicated in neuronal survival and synapse formation and function suggests that astrocytes may be potential targets for mediating the actions of flavonoids. Therefore, manipulation of astrocyte physiology can represent an important therapeutic tool for the injured CNS.
Many lines of evidence suggest that astrocytes are important cellular targets of flavonoids. We have previously shown that the treatment of neural progenitor cells with conditioned medium derived from casticin-treated astrocytes increased the neuronal population and decreased cell death in vitro (de Sampaio e Spohr et al., 2010; Nones et al., 2012b) . Similar data were reported by studies in cultured progenitor cells maintained in conditioned medium from hesperidin treated-astrocytes (de Sampaio e Spohr et al., 2010; Nones et al., 2012b) . These data suggest that flavonoids induce the secretion of neuroprotective soluble factors by astrocytes and other molecules that may modulate cell differentiation (de Sampaio e Spohr et al., 2010; Nones et al., 2012b) . Although the nature of these soluble factors is still unknown, several studies have shown that some natural compounds and synthetic drugs regulate the synthesis and secretion of neurotrophins by astrocytes (Corbett et al., 2013; Modi et al., 2013) .
Neurotrophic factors are mainly synthesized and secreted by neurons and astrocytes and they modulate important functions involving growth, differentiation, survival and synaptic plasticity. However, a decrease in neurotrophic factors has been reported in some neurodegenerative and psychiatric diseases. Therefore, the regulation of the levels of these molecules is critical to brain function and the actions of natural compounds on the regulation of secretion of these factors by astrocytes have important therapeutic implications. Resveratrol, a non-flavonoid polyphenol, induced the secretion of BDNF and glial-derived neurotrophic factor (GDNF) in cultured astrocytes (Zhang et al., 2012) . A screen of thirty-three flavonoids from different subclasses showed that most of them were able to induce the secretion of GDNF, nerve growth factor (NGF) and/or BDNF by astrocytes. Calycosin, isorhamnetin, luteolin and genistein were the most active in inducing the secretion of these three factors in higher concentrations (Xu et al., 2013a) .
In addition to the regulation of neurotrophin secretion, glial cells, astrocytes and microglia, are notable sources of cytokines in the CNS. Neuroinflammation is an important event in the pathogenesis of most neurological diseases, whether acute, such as stroke, brain trauma and meningitis, or chronic, such as Alzheimer's disease, multiple sclerosis and Parkinson's disease. Furthermore, glial reactivity, astrogliosis and microgliosis, are classic markers for pathological process and aging of the nervous system (Ritzel et al., 2015; . Reactive astrocytes display phenotypic changes characterized by hypertrophic cell bodies and nuclei, cell processes emission and increased GFAP expression (Pekny and Nilsson, 2005) . They participate in the inflammatory response by secreting various cytokines, notably TNF-a and interleukin-1 beta (IL-1b) and generating reactive species, especially nitric oxide (NO), by increasing the activity of inducible nitric oxide synthase (iNOS) (Dong and Benveniste, 2001) . In this sense, the control of glial reactivity could impact neuroinflammation and some studies have shown that natural compounds can be relevant to this purpose (Nones et al., 2010) .
The flavonoids quercetin and luteolin attenuated the inflammatory profile of astrocytes exposed to IL-1b, as observed by the reduced production of reactive oxygen species, increased expression of the antioxidant enzymes SOD1 and thioredoxin 1, and reduced secretion of proinflammatory cytokines and chemokines. In addition, flavonoids have been shown to prevent the increase in GFAP expression in astrocytes exposed to IL-1b (Sharma et al., 2007) . The flavonoid (À)epicatechin has also been shown to prevent the inflammatory profile of astrocytes due to the increased expression of genes involved in anti-oxidant cellular response as well as the increased levels of the antioxidant enzyme, glutathione, in cortical astrocytes (Bahia et al., 2008) . Using a neuron-glial coculture system, it has been demonstrated that the pre-treatment of glial cells by LPS/IFN-g strongly increased their production of TNF-a and NO, an event dependent on the activation of p38 mitogenactivated protein kinase (MAPK) and the signal transducer and activator of transcription-1 (STAT-1). However, the flavanone naringenin has been shown to attenuate the pro-inflammatory profile of those astrocytes and microglia through the inhibition of p38 and STAT-1, and consequently it was able to prevent the neuronal injury (Vafeiadou et al., 2009 ).
Furthermore, in vivo studies corroborate the potential of astrocytes as targets for natural compounds and regulators of neuroinflammation in pathological conditions and in the aging brain (Currais et al., 2014) . In recent years, the non-flavonoid polyphenol resveratrol has received great attention for its potential to modulate neuroinflammation and promote cognitive benefits in different animal models (Saiko et al., 2008) . A recent study has shown that the chronic administration of resveratrol in late middle-aged mice attenuated astrocytic and microglial activation as well as increased hippocampal neurogenesis compared to untreated animals of the same age. These actions induced the cognitive improvement of resveratrol-treated animals (Kodali et al., 2015) . Therefore, a number of studies have reinforced the potential of natural compounds to modulate glial cell function and restore brain function (Blackburn et al., 2009; Sloan and Barres, 2014) . Nevertheless, our understanding of the cellular and molecular targets for the actions of natural compounds in the nervous system still remains unclear, and we are still far from fully understanding the full potential of these compounds to restore brain function.
Concluding remarks
In recent years, a breakthrough in the understanding of the functions of glial cells has occurred. Astrocytes, initially viewed solely as neuronal support cells, are now recognized as crucial cells for homeostatic and functional control of the nervous system. These cells compose the BBB, participate in the immune response, control neurotransmitter levels in the synaptic cleft and actively regulate the formation, refinement and plasticity of synapses.
Glial dysfunction has been recently associated with several brain diseases. The inflammatory response involving astrocytes and microglia strongly contributes to the progression of Alzheimer's disease, Parkinson's disease, ALS and multiple sclerosis (Glass et al., 2010) . Recently, it has been shown that astroglial dysfunction is also associated with intellectual disability in Down's syndrome (DS). DS astroglia exhibit higher levels of reactive oxygen species and lower levels of synaptogenic molecules such as TSP1 and TSP2, leading to The promotion of the differentiation of progenitor neural cells into neurons and the reduction of neuronal death and the increase of neurogenesis and synaptic plasticity in the adulthood, leading to increased synaptic function; 2. The induction of the secretion of soluble factors by astrocytes that act indirectly on neurons, increasing differentiation and reducing death; the effects of flavonoids on synaptic function remain unknown; 3. The reduction of astrocytic reactivity and the increase in the antioxidant response; additionally, these compounds are able to increase the secretion of neuroprotective factors by astrocytes, although the identity of these factors remains unknown; 4. The decrease in the microglial activation and secretion of pro-inflammatory cytokines by these cells. the abnormal development of dendritic spines and the reduced activity and density of synapses (Chen et al., 2014; Garcia et al., 2010) . Interestingly, several of these abnormalities were prevented by the presence of normal astrocytes (Chen et al., 2014) .
Reduced TSP-1 levels have also been found in the brains of Alzheimer's disease patients (Buee et al., 1992) , and astrocytes exposed to amyloid beta (Ab) display a deficiency in TSP-1 secretion (Rama Rao et al., 2013) . Consistent with these observations, a recent study has shown that the restoration of TSP-1 levels is able to prevent the synaptic deficits observed in a rodent model of Alzheimer's disease. Taken together, these studies strongly indicate that TSP-1 is a possible therapeutic agent for Alzheimer's disease and that astrocytes play an important role in this disease (Son et al., 2015) , thus supporting the manipulation of astrocyte biology as an alternative for the treatment of neural diseases.
Several studies have sought to evaluate the action of drugs with potential therapeutic use on astrocyte biology. These include natural compounds, especially flavonoids, which have emerged as potential modulators of brain function. The increase in neurotrophic factor levels in the brain is considered a potential therapeutic mechanism for neurodegenerative diseases, thus making astrocytes important targets because they are the main source of these factors in the brain. This suggestion is supported by the findings that some flavonoids induce the secretion of soluble factors by astrocytes in vitro, and increase their levels in the brain in vivo. Additionally, flavonoids attenuate the activation of astrocytes and microglia in animal models of neurodegenerative diseases (Chakraborty et al., 2014; Lee et al., 2014 Lee et al., , 2013 Liu et al., 2011) (Fig. 1) .
The recent findings that astrocytes are targets for flavonoids and that they are associated with several diseases clearly support the development of new therapeutic protocols based on astrocytespecific cell replacement and function. Whether glial dysfunction is the cause or the consequence of the pathological states is still a subject of discussion. However, the association between glial dysfunction and brain pathology and aging clearly indicates that the mechanisms that underlie neuroneastrocyte interactions deserves our attention and may point to new preventive and therapeutic prospects for neurological diseases. The identification of molecules such as natural compounds that are able to modulate astrocyte biology might open an important avenue to halt the negative effects of aging and to restore the injured brain.
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